



Notice of Full Year Results

March 15, 2018

Released : March 15, 2018 07:00

RNS Number : 7489H

MaxCyte, Inc.

15 March 2018

MaxCyte, Inc.
("MaxCyte" or the "Company")

Notice of Full Year Results

Gaithersburg, Maryland - 15 March 2018: MaxCyte (LSE: MXCT, MXCR), a global cell-based medicines and life sciences company, will be announcing its full year audited results for the year ended 31 December 2017 on Wednesday 4 April 2018.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

+1 301 944 1660

Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

+44 (0) 20 7886 2500

Ryan McCarthy

Tom Salvesen (Corporate Broking)

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Suki Virji

+44 (0)203 709 5700

maxcyte@consilium-comms.com**About MaxCyte**

MaxCyte (LSE: MXCT, MXCR) is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licenses in cell therapy including more than 20 licensed for clinical use in cell therapy. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit <http://www.maxcyte.com/>.

This information is provided by RNS
The company news service from the London Stock Exchange

END

NORJIMATMBBBBBP